Lack of Tacrolimus Circadian Pharmacokinetics and CYP3A5 Pharmacogenetics in the Early and Maintenance Stages in Renal Transplant Recipients.

被引：0
|
作者：
Satoh, Shigeru [1 ]
Saito, Mitsuru [1 ]
Kagaya, Hideaki [2 ]
Miura, Masatomo [2 ]
Inoue, Takamitsu [1 ]
Miura, Yoshio [1 ]
Numakura, Kazuyuki [1 ]
Kumazawa, Teruaki [1 ]
Tsuchiya, Norihiko [1 ]
Habuchi, Tomonori [1 ]
机构：
[1] Akita Univ, Sch Med, Akita 010, Japan
[2] Akita Univ Hosp, Akita, Japan
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2009年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：590 / 590
页数：1
相关论文
共 50 条
  • [21] Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
    Roy, Jean Nicholas
    Barama, Azemi
    Poirier, Charles
    Vinet, Bernard
    Roger, Michel
    PHARMACOGENETICS AND GENOMICS, 2006, 16 (09): : 659 - 665
  • [22] CYP3A5 polymorphism and tacrolimus pharmacokinetic/pharmacodynamic interactions in young kidney transplant recipients.
    Ghio, L.
    Ferraresso, M.
    Tirelli, S.
    Grillo, P.
    Belingheri, M.
    Martina, V.
    Torresani, E.
    Berardinelli, L.
    Edefonti, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 577 - 577
  • [23] Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients
    Shi, Yunying
    Li, Yi
    Tang, Jiangtao
    Zhang, Junlong
    Zou, Yuangao
    Cai, Bei
    Wang, Lanlan
    GENE, 2013, 512 (02) : 226 - 231
  • [24] IN VIVO CYP3A4-ACTIVITY AND CYP3A5-GENOTYPE PREDICT TACROLIMUS PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS.
    de Jonge, H.
    de Loor, H.
    Verbeke, K.
    Vanrenterghem, Y.
    Kuypers, D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S5 - S5
  • [25] IN VIVO CYP3A4-ACTIVITY AND CYP3A5-GENOTYPE PREDICT TACROLIMUS PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS.
    de Jonge, H.
    de Loor, H.
    Verbeke, K.
    Vanrenterghem, Y.
    Kuypers, D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S49 - S50
  • [26] Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients
    Ferraresso, Mariano
    Tirelli, Amedea
    Ghio, Luciana
    Grillo, Paolo
    Martina, Valentina
    Torresani, Erminio
    Edefonti, Alberto
    PEDIATRIC TRANSPLANTATION, 2007, 11 (03) : 296 - 300
  • [27] CYP3A5/ABCB1 Combined Genotype Has Similar Influence On Pharmacokinetics of Immediate and Prolonged Release Tacrolimus in Renal Transplant Recipients.
    Elnahhas, T.
    Moreton, M.
    Lee, T.
    McKeown, D.
    Popoola, J.
    Ramkhelawon, R.
    Johnston, A.
    MacPhee, I.
    TRANSPLANTATION, 2014, 98 : 548 - 548
  • [28] CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
    Renders, L.
    Frisman, M.
    Ufer, M.
    Mosyagin, I.
    Haenisch, S.
    Ott, U.
    Caliebe, A.
    Dechant, M.
    Braun, F.
    Kunzendorf, U.
    Cascorbi, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) : 228 - 234
  • [29] Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre
    Cheng, Y.
    Li, H.
    Meng, Y.
    Liu, H.
    Yang, L.
    Xu, T.
    Yu, J.
    Zhao, N.
    Liu, Y.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 : 16 - 22
  • [30] The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients
    Zhang, Jing-Jing
    Liu, Shuai-Bing
    Xue, Ling
    Ding, Xiao-Liang
    Zhang, Hua
    Miao, Li-Yan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (09) : 728 - 736
12345